The ability of PPAR-γ agonists to reduce neuroinflammation, Aβ-42, phosphorylated tau, and synaptophysin, with resulting improvement in spatial memory, as well as motor function, has been demonstrated in AD mouse models (Chang et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.